- Report
- October 2024
- 192 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- February 2022
- 80 Pages
Global
From €2636EUR$2,750USD£2,203GBP
€5273EUR$5,500USD£4,406GBP
- Report
- June 2024
Global
From €815EUR$850USD£681GBP
- Report
- March 2024
- 132 Pages
Global
From €911EUR$950USD£761GBP
The Lipoprotein A Test market within the Point-of-Care Diagnostics sector is a rapidly growing segment of the healthcare industry. This test is used to measure the amount of lipoprotein A (Lp(a)) in the blood, which is a risk factor for cardiovascular disease. The test is used to identify individuals at risk of developing cardiovascular disease, and to monitor the effectiveness of treatments. The test is typically performed in a doctor's office or clinic, and the results are available within minutes.
The Lipoprotein A Test market is driven by the increasing prevalence of cardiovascular disease, as well as the need for rapid diagnosis and treatment. The market is expected to continue to grow as more healthcare providers adopt the technology.
Some companies in the Lipoprotein A Test market include Abbott, Roche, Siemens, and Alere. Show Less Read more